ENGLEWOOD, Colo., June 15 /PRNewswire/ -- The ValiMed Medication Validation System and related information are now available at http://publicrelationsnewsroom.com/_wsn/page19.html for media and professional access. ValiMed, distributed by Baxa Corporation, uses enhanced photoemission spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the Medication Signature Library and returns an easy-to-understand “validated” or “not validated” result, requiring no user interpretation.
The expanded ValiMed System features patented technology that validates in seconds compounded doses of high-risk medications prior to dispensing. Verification of compounding accuracy is a requirement under USP 27-NF 22 Chapter 797, which regulates the compounding of sterile products.
“This next-generation ValiMed System addresses customer requests,” notes Baxa Corporation Product Manager Mark Thrasher. “The addition of a quality assurance feature meets the regulatory requirements, while the smaller sample requirement more easily accommodates current pharmacy work flows.”
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Finland, France, Germany, Luxembourg and The Netherlands; and distribution partners worldwide. Further information is available at http://www.baxa.com.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (I) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (II) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. For more information, visit http://www.cdex-inc.com and http://www.valimed.com.
Contacts: Baxa Corporation Marian Robinson, Vice President, Marketing Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157 Email: marian.robinson@baxa.comhttp://www.baxa.com Maggie Chamberlin Holben, APR, Absolutely Public Relations 303.984.9801, 303.669.3558 Email: maggie@absolutelypr.comhttp://www.absolutelypr.com CDEX Inc. Malcolm Philips or Stuart Poteet 520.745.5172 mphilips@cdex-inc.comspoteet@cdex-inc.comhttp://www.cdex-inc.com
Baxa Corporation
CONTACT: Marian Robinson, Vice President, Marketing of Baxa Corporation,1-800-567-2292 ext. 2157, or +1-303-617-2157, marian.robinson@baxa.com; orMaggie Chamberlin Holben, APR of Absolutely Public Relations,+1-303-984-9801, or +1-303-669-3558, maggie@absolutelypr.com, for BaxaCorporation; or Malcolm Philips or Stuart Poteet of CDEX Inc.,+1-520-745-5172, mphilips@cdex-inc.com, spoteet@cdex-inc.com
